Tetsunari Hase

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7014900/publications.pdf Version: 2024-02-01



TETSUNADI HASE

#	Article	IF	CITATIONS
1	SRGN-Triggered Aggressive and Immunosuppressive Phenotype in a Subset of TTF-1–Negative Lung Adenocarcinomas. Journal of the National Cancer Institute, 2022, 114, 290-301.	3.0	18
2	Immune-related Liver Injury is a Poor Prognostic Factor in Patients with Nonsmall Cell Lung Cancer Treated with Immune Checkpoint Inhibitors. Cancer Investigation, 2022, 40, 189-198.	0.6	9
3	Increased Risk of Thyroid Dysfunction by PD-1 and CTLA-4 Blockade in Patients Without Thyroid Autoantibodies at Baseline. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e1620-e1630.	1.8	15
4	Meflin-positive cancer-associated fibroblasts enhance tumor response to immune checkpoint blockade. Life Science Alliance, 2022, 5, e202101230.	1.3	16
5	Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis. BMC Cancer, 2022, 22, .	1.1	17
6	Comparing incidences of infusion site reactions between brandâ€name and generic vinorelbine in patients with nonâ€small cell lung cancer. British Journal of Clinical Pharmacology, 2021, 87, 1318-1326.	1.1	1
7	Efficacies of programmed cell death 1 ligand 1 blockade in non-small cell lung cancer patients with acquired resistance to prior programmed cell death 1 inhibitor and development of diabetic ketoacidosis caused by two different etiologies: a retrospective case series. Endocrine Journal, 2021, 68, 613-620.	0.7	8
8	Clinical value of serum bone resorption markers for predicting clinical outcomes after use of bone modifying agents in metastatic bone tumors: A prospective cohort study. International Journal of Cancer, 2020, 146, 3504-3515.	2.3	5
9	Potential Benefits of Bevacizumab Combined With Platinum-Based Chemotherapy in Advanced Non–Small-Cell Lung Cancer Patients With EGFR Mutation. Clinical Lung Cancer, 2020, 21, 273-280.e4.	1.1	21
10	Short hydration with 20ÂmEq of magnesium supplementation for lung cancer patients receiving cisplatin-based chemotherapy: a prospective study. International Journal of Clinical Oncology, 2020, 25, 1928-1935.	1.0	10
11	Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study. , 2020, 8, e000779.		75
12	Real world data of liver injury induced by immune checkpoint inhibitors in Japanese patients with advanced malignancies. Journal of Gastroenterology, 2020, 55, 653-661.	2.3	38
13	Anti-thyroid antibodies and thyroid echo pattern at baseline as risk factors for thyroid dysfunction induced by anti-programmed cell death-1 antibodies: a prospective study. British Journal of Cancer, 2020, 122, 771-777.	2.9	48
14	Development of an immuno-wall device for the rapid and sensitive detection of EGFR mutations in tumor tissues resected from lung cancer patients. PLoS ONE, 2020, 15, e0241422.	1.1	3
15	Title is missing!. , 2020, 15, e0241422.		0
16	Title is missing!. , 2020, 15, e0241422.		0
17	Title is missing!. , 2020, 15, e0241422.		0

Tetsunari Hase

#	Article	IF	CITATIONS
19	BK virus-associated viruria and viremia in a patient with lymphangioleiomyomatosis after lung re-transplantation: A case report and review of the literature on BK virus infection post-lung transplantation. Journal of Infection and Chemotherapy, 2019, 25, 820-824.	0.8	2
20	Potential for afatinib as an optimal treatment for advanced non-small cell lung carcinoma in patients with uncommon EGFR mutations. Lung Cancer, 2019, 127, 169-171.	0.9	21
21	A 65-nm CMOS Fully Integrated Analysis Platform Using an On-Chip Vector Network Analyzer and a Transmission-Line-Based Detection Window for Analyzing Circulating Tumor Cell and Exosome. IEEE Transactions on Biomedical Circuits and Systems, 2019, 13, 470-479.	2.7	13
22	Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study. Journal of the Endocrine Society, 2018, 2, 241-251.	0.1	146
23	<i><scp>elF</scp>2</i> β, a subunit of translationâ€initiation factor <scp>ElF</scp> 2, is a potential therapeutic target for nonâ€small cell lung cancer. Cancer Science, 2018, 109, 1843-1852.	1.7	20
24	Pivotal role of epithelial cell adhesion molecule in the survival of lung cancer cells. Cancer Science, 2011, 102, 1493-1500.	1.7	24